Skip to main content

UPDATE 3-Akorn row overshadows Fresenius' generics guidance

* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.